Review



plko tet on vectors  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Addgene inc plko tet on vectors
    Plko Tet On Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 62 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plko tet on vectors/product/Addgene inc
    Average 94 stars, based on 62 article reviews
    plko tet on vectors - by Bioz Stars, 2026-05
    94/100 stars

    Images



    Similar Products

    94
    Addgene inc plko tet on vectors
    Plko Tet On Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plko tet on vectors/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    plko tet on vectors - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    Addgene inc lentiviral expression vector pcw cas9 blast
    Lentiviral Expression Vector Pcw Cas9 Blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lentiviral expression vector pcw cas9 blast/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    lentiviral expression vector pcw cas9 blast - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    Addgene inc lentiviral expression vector pcw cas9blast
    Lentiviral Expression Vector Pcw Cas9blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lentiviral expression vector pcw cas9blast/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    lentiviral expression vector pcw cas9blast - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    Addgene inc pcw cas9 blast vector
    Pcw Cas9 Blast Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pcw cas9 blast vector/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    pcw cas9 blast vector - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    Addgene inc inducible cas9 vector
    FBXO45 deficiency sensitizes BCL to MAPK pathway inhibition in vitro and in vivo . A, FBXO45 WT or <t>CRISPR-Cas9–mediated</t> FBXO45 KO iBJAB (“i”, doxycycline-inducible Cas9 expression) cells were treated with cycloheximide (CHX), and WCE was analyzed by WB with indicated antibodies. B, FBXO45 WT and KO iBJAB cells were treated with trametinib as indicated, and WCEs were analyzed by WB with the indicated antibodies. C, FBXO45 WT and KO iBJAB cells were xenografted in NSG mice and treated with trametinib as detailed in the “Methods” section. Tumor volumes of mice treated with trametinib for both FBXO45 WT and KO ( n = 6 each) were individually measured every 3 days. Experiments were performed in triplicate. D, In vivo imaging studies at day 25 show decreased tumor sizes in response to trametinib treatment in FBXO45 KO xenografts. At the end of the study (day 25), tumors were surgically removed for imaging analysis, as shown in the right panel. E, The top panel shows a schematic illustration of the experimental plan to evaluate trametinib treatment on xenograft tumors originated by FL518-CBG luciferase cells. The bottom panel shows representative BLI at days 1,6, 8 and 13. F, Relative bioluminescence (RLU or relative luminescence units) for each group of mice was measured and plotted for day 13. Two-tailed Mann–Whitney unpaired Student’s t test was used for analysis (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001). G, Kaplan–Meier survival curves of NS shRNA and FBXO45 shRNA expressing FL518-derived lymphoma xenografts in SCID-BEIGE mice. Log-rank (Mantel–Cox) test was used for analysis. WB, Western blotting; WCE, whole cell extract. Dox, doxycycline; ns, not significant.
    Inducible Cas9 Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inducible cas9 vector/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    inducible cas9 vector - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    Addgene inc plko based sgrna vector
    Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout <t>sgRNA</t> Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.
    Plko Based Sgrna Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plko based sgrna vector/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    plko based sgrna vector - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    Addgene inc pcw cas9 tet on vector
    Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout <t>sgRNA</t> Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.
    Pcw Cas9 Tet On Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pcw cas9 tet on vector/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    pcw cas9 tet on vector - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    Addgene inc cumate inducible lentiviral vectors
    Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout <t>sgRNA</t> Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.
    Cumate Inducible Lentiviral Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cumate inducible lentiviral vectors/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    cumate inducible lentiviral vectors - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    Image Search Results


    FBXO45 deficiency sensitizes BCL to MAPK pathway inhibition in vitro and in vivo . A, FBXO45 WT or CRISPR-Cas9–mediated FBXO45 KO iBJAB (“i”, doxycycline-inducible Cas9 expression) cells were treated with cycloheximide (CHX), and WCE was analyzed by WB with indicated antibodies. B, FBXO45 WT and KO iBJAB cells were treated with trametinib as indicated, and WCEs were analyzed by WB with the indicated antibodies. C, FBXO45 WT and KO iBJAB cells were xenografted in NSG mice and treated with trametinib as detailed in the “Methods” section. Tumor volumes of mice treated with trametinib for both FBXO45 WT and KO ( n = 6 each) were individually measured every 3 days. Experiments were performed in triplicate. D, In vivo imaging studies at day 25 show decreased tumor sizes in response to trametinib treatment in FBXO45 KO xenografts. At the end of the study (day 25), tumors were surgically removed for imaging analysis, as shown in the right panel. E, The top panel shows a schematic illustration of the experimental plan to evaluate trametinib treatment on xenograft tumors originated by FL518-CBG luciferase cells. The bottom panel shows representative BLI at days 1,6, 8 and 13. F, Relative bioluminescence (RLU or relative luminescence units) for each group of mice was measured and plotted for day 13. Two-tailed Mann–Whitney unpaired Student’s t test was used for analysis (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001). G, Kaplan–Meier survival curves of NS shRNA and FBXO45 shRNA expressing FL518-derived lymphoma xenografts in SCID-BEIGE mice. Log-rank (Mantel–Cox) test was used for analysis. WB, Western blotting; WCE, whole cell extract. Dox, doxycycline; ns, not significant.

    Journal: Cancer Discovery

    Article Title: The FBXO45–GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis

    doi: 10.1158/2159-8290.CD-24-0442

    Figure Lengend Snippet: FBXO45 deficiency sensitizes BCL to MAPK pathway inhibition in vitro and in vivo . A, FBXO45 WT or CRISPR-Cas9–mediated FBXO45 KO iBJAB (“i”, doxycycline-inducible Cas9 expression) cells were treated with cycloheximide (CHX), and WCE was analyzed by WB with indicated antibodies. B, FBXO45 WT and KO iBJAB cells were treated with trametinib as indicated, and WCEs were analyzed by WB with the indicated antibodies. C, FBXO45 WT and KO iBJAB cells were xenografted in NSG mice and treated with trametinib as detailed in the “Methods” section. Tumor volumes of mice treated with trametinib for both FBXO45 WT and KO ( n = 6 each) were individually measured every 3 days. Experiments were performed in triplicate. D, In vivo imaging studies at day 25 show decreased tumor sizes in response to trametinib treatment in FBXO45 KO xenografts. At the end of the study (day 25), tumors were surgically removed for imaging analysis, as shown in the right panel. E, The top panel shows a schematic illustration of the experimental plan to evaluate trametinib treatment on xenograft tumors originated by FL518-CBG luciferase cells. The bottom panel shows representative BLI at days 1,6, 8 and 13. F, Relative bioluminescence (RLU or relative luminescence units) for each group of mice was measured and plotted for day 13. Two-tailed Mann–Whitney unpaired Student’s t test was used for analysis (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001). G, Kaplan–Meier survival curves of NS shRNA and FBXO45 shRNA expressing FL518-derived lymphoma xenografts in SCID-BEIGE mice. Log-rank (Mantel–Cox) test was used for analysis. WB, Western blotting; WCE, whole cell extract. Dox, doxycycline; ns, not significant.

    Article Snippet: Lentiviral packaging plasmids pMD2.G (RRID: Addgene_12259), psPAX2 (RRID: Addgene_12260), and inducible Cas9 vector (RRID: Addgene_83481) were obtained from Addgene.

    Techniques: Inhibition, In Vitro, In Vivo, CRISPR, Expressing, In Vivo Imaging, Imaging, Luciferase, Two Tailed Test, MANN-WHITNEY, shRNA, Derivative Assay, Western Blot

    Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout sgRNA Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.

    Journal: Journal for immunotherapy of cancer

    Article Title: Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing.

    doi: 10.1136/jitc-2024-010699

    Figure Lengend Snippet: Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout sgRNA Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.

    Article Snippet: The cells were then maintained at 37°C in an atmosphere containing 5% CO2. pCW- Cas9 blast and pLKO- based sgRNA vector were purchased from Addgene (plasmid #83481 and #52628, respectively).

    Techniques: Genome Wide, CRISPR, Transduction, Knock-Out, Mutagenesis, Lysis, Co-Culture Assay, Sequencing